First Patient Enrolled in FIERCE-HN Trial of Ficlatuzumab + ERBITUX® (cetuximab) in Patients with HPV-negative R/M HNSCC January 25, 2024
Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma December 19, 2023
STELLAR-305 Ph 2/3 Pivotal Trial of Zanzalintinib + Keytruda in Patients with 1L Recurrent or Metastatic Head and Neck Cancer announced December 11, 2023
Patient Enrollment in Global Ph 3 Trial of Buparlisib (AN2025) + Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC completed December 11, 2023
Interim Data from Ph 1b/2 Clinical Trial of Nana-val in Patients with EBV+ve Solid Tumors Show Confirmed Tumor Responses at Higher Dose Levels December 11, 2023
FDA approves LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) October 31, 2023
First Patient Dosed in Ph 1/2a Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer September 26, 2023
FAILED TRIAL: Phase 3 LEAP-010 Trial of LENVIMA + KEYTRUDA in Patients With Certain Types of Recurrent or mSCCHN unlikely to meet primary endpoint of OS September 6, 2023
LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand July 27, 2023
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Radioenhancer NBTXR3 July 19, 2023
Efficacy Threshold achieved in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer June 21, 2023
Enrollment completed in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer May 31, 2023
Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients May 31, 2023
Encouraging early efficacy data from ModiFY Ph 1/2 trial announced: Modi-1 monotherapy showed PR and SD in SCCHN, ovarian, or TNBC patients February 22, 2023
Positive Final OS Results of Ph 3 JUPITER-02 Trial of Toripalimab as Treatment for Recurrent or mNPC announced February 22, 2023
50% Enrollment completed in Randomised Ph IIb TACTI-003 Trial for 1L Head & Neck Cancer January 11, 2023
BLA Review for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) by FDA remains pending January 4, 2023
Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs December 19, 2022
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 + KEYTRUDA® in Patients with HPV16-Positive Head and Neck Cancer December 13, 2022
New Positive Data from Ongoing Ph 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer presented November 16, 2022
